The use of mannitol in cardiopulmonary bypass prime solution-Prospective randomized double-blind clinical trial.

"CONFLICT OF INTEREST The authors have no conflicts of interest."

"Funding information"

"This single‐center, prospective study was designed as a randomized double‐blind, control trial. The study was approved by the ethics committee of southern Sweden (no. 2017/442), and was also reported to ClinicalTrials.org, id: NCT03302286. We recruited 40 adult patients who were scheduled for elective isolated coronary artery bypass grafting (CABG) at the Department of Cardiothoracic Surgery, Anesthesia and Intensive Care, Skane University Hospital, Lund, Sweden. The flowchart for the study is presented in Figure . All patients were informed orally and in writing prior to surgery by the authors, and written consent was obtained for study participation and publishing of the results. Data collection started in September 2017 and was completed by March 2018. Twenty patients were allocated to each arm using the sealed envelope system. Coding was performed by non‐study staff and code key was revealed after the end of data collection. Randomization was performed by non‐study clinical staff who prepared the study solution and gave this to the blinded perfusionist. The inclusion criteria were as follows: normal left ventricular function, defined as a left ventricular ejection fraction on preoperative echocardiogram of at least 50%, and normal renal function, defined as estimated glomerular filtration rate (eGFR) greater than 60 mL/min. Exclusion criteria were patient weight less than 50 kg, preoperative hematocrit less than 24% and previous history of cardiac surgery. In our study, the eGFR was the mean of the relative eGFR based on creatinine and the relative eGFR based on cystatin C. The revised Lund‐Malmö equation was used to calculate eGFR based on creatinine and the CAPA equation was used to calculate eGFR based on cystatin C."